We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Quantum Phar. | LSE:QP. | London | Ordinary Share | GB00BRTL8Q42 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 84.2374 | 84.00 | 84.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMQP.
RNS Number : 4255D
Quantum Pharma PLC
26 April 2017
For immediate release 26 April 2017
Quantum Pharma Plc
('Quantum' or the 'Group')
Administration of NuPharm
Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier, announces that following the cessation of trading at NuPharm Laboratories Limited ('NuPharm') in January, NuPharm was placed into administration earlier today. In accordance with paragraph (g) of Schedule 2 of the AIM Rules for Companies, Quantum confirms that Chris Rigg, CEO, was also a director of NuPharm when it was placed into administration.
- Ends -
Hot Features
Premium
For further information:
Quantum Pharma Plc
Chris Rigg, Chief Executive Tel: +44 (0) 1207 279
Officer 404
Gerard Murray, Chief www.quantumpharmaplc.com
Financial Officer
ir@quantumpharma.co.uk
N+1 Singer
(Nominated Advisor & Broker)
Sandy Fraser / Nick Owen Tel: +44 (0) 20 7496
/ James White 3000
Media enquiries:
Buchanan
Henry Harrison-Topham Tel: +44 (0) 20 7466
5000
quantumpharma@buchanan.uk.com www.buchanan.uk.com
Notes to Editors
Quantum Pharma is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions - Specials, Niche Pharmaceuticals and Medication Adherence - offering a portfolio of innovative and complementary products and services.
For further information, please visit www.quantumpharmagroup.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEAFDMFWSESL
(END) Dow Jones Newswires
April 26, 2017 09:15 ET (13:15 GMT)
1 Year Quantum Phar. Chart |
1 Month Quantum Phar. Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
